Clinical Trials
Currently Recruiting
-
ADP-0000-001
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Principal Investigator: Dr. Marcus Butler
NCT#: NCT02636855
-
ADP-0055-001
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Principal Investigator: Dr. Marcus Butler
NCT#: NCT04044859
-
ADP-0044-002
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Principal Investigator: Dr. Albiruni Razak
NCT#: NCT04044768
-
IOV-COM-202
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT03645928
-
IMCnyeso-101
A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer
Principal Investigator: Dr. Marcus Butler
NCT#: NCT03515551
-
GSK208467
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Principal Investigator: Dr. Albiruni Razak
NCT#: NCT03967223
-
GSK208750
Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT03391778
-
SQZ-PBMC-HPV-101
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Principal Investigator: Dr. Neesha Dhani
NCT#: NCT04084951
-
CRSP-ONC-003
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT04438083
-
TCR2-18-01
A Phase 1/2 Single Arm Open-Label Clinical Trial of Tc-210 T Cells In Patients with Advanced Mesothelin-Expressing Cancer
Principal Investigator: Dr. Marcus Butler
NCT#: NCT03907852